AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21087288
Drug: NETE-6/12 (norethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NETE-6/12 (norethisterone enanthate 200 mg every 6 weeks for 12 weeks and then every 12 weeks plus testosterone undecanoate 1000 mg)
Trial: 21087288
Drug: NETE-6/12/0 (norethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NETE-6/12/0 (norethisterone enanthate 200 mg every 6 weeks for 12 weeks and then testosterone undecanoate plus placebo every 12 weeks)
Trial: 16995976
Drug: Combined non-biological
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined non-biological artificial liver treatment
Trial: 16995976
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no combined non-biological artificial liver treatment)
Trial: 9024169
Drug: Triazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.5 mg) after rifampin (600 mg once daily for 5 days)
Trial: 8101045
Drug: Flumazenil administered
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil administered intravenously in small, incremental doses
Trial: 24956863
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (surgical treatment + chemotherapy regimen PTX + EPI + CTX)
Trial: 21131072
Drug: PCI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI with tirofiban infusion (TI)
Trial: 21131072
Drug: PCI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCI with both treatments (IT+TI)
Trial: 21131072
Drug: Tirofiban infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban infusion (TI)
Trial: 16324409
Drug: Glucosamine hydrochloride
RxNorm normalized name: Glucosamine Hydrochloride
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine hydrochloride (GH) 1440 mg/day for 4 weeks
Trial: 16324409
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate (GS) 1500 mg/day for 4 weeks
Trial: 12934980
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg/day increased to 60 mg/day)
Trial: 12934980
Drug: Citalopram (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (continued treatment)
Trial: 10848459
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (patrol response)
Trial: 8848916
Drug: Intrathecal (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal (0.4 mg) and intramuscular (4 mg) morphine (IT‐IM‐group)
Trial: 8848916
Drug: Intrathecal (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal (0.4 mg) morphine and intramuscular saline (IT‐group)
Trial: 8848916
Drug: Intrathecal (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal (0.4 mg) morphine (IT‐group)
Trial: 6438851
Drug: Ifosfamide (IF)
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide (IF) at 1.8 g/m2 days 1‐5 q 4 weeks with Mesna (0.36 g/m2 i.v. or 0.72 g/m2 orally) given after each IF injection.
Trial: 6438851
Drug: Ifosfamide +
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide + Mesna combination
Trial: 30967589
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy sessions
Trial: 12039990
Drug: Active vitamin
RxNorm normalized name: OCTOCRYLENE 70 mg in 1 mL / HOMOSALATE 50 mg in 1 mL / OCTISALATE 50 mg in 1 mL / AVOBENZONE 30 mg in 1 mL TOPICAL CREAM [Garnier SkinActive Vitamin(E) C UV Brightening Daily Broad Spectrum SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active vitamin D (0.25 microg/d) plus calcium (1000 mg/d)
Trial: 12039990
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (NoT group)
Trial: 7981510
Drug: Superparamagnetic iron
RxNorm normalized name: Superparamagnetic iron oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superparamagnetic iron oxide (SHU 555 A) at doses of 5, 10, 20, and 40 mumol/kg
Trial: 2689345
Drug: Aztreonam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam (1 g i.v. bolus t.i.d. for a mean of 8.2 days)
Trial: 2689345
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g i.v. bolus t.i.d. for a mean of 8.2 days)
Trial: 31187152
Drug: IV THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV THC (0.05 mg/kg)
Trial: 31187152
Drug: Tolcapone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolcapone (200 mg) followed by IV THC
Trial: 28594714
Drug: Standard radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiochemotherapy (Cap 50: 50 Gy irradiation and 1600 mg/m oral capecitabine daily) plus surgery (arm B)
Trial: 21350408
Drug: Cytoflavin (infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (infusion solution) prescribed in the first 2‐4 hours after delivery to 61 newborns
Trial: 21350408
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (59 newborns who did not receive the drug)
Trial: 17253066
Drug: Intrarectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal lidocaine gel (10cc)
Trial: 17253066
Drug: Periprostatic lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periprostatic lidocaine injection (1% in 10cc)
Trial: 14587264
Drug: Clopidogrel 300
RxNorm normalized name: clopidogrel 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 300 mg loading dose given at least 6 hours before PCI
Trial: 14587264
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg once daily after PCI
Trial: 14587264
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the loading dose of clopidogrel if intervention must be undertaken sooner
Trial: 10893283
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus vinorelbine (G + V)
Trial: 1579323
Drug: Cyclic treatment
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic treatment with 2 mg of estradiol valerate for 3 weeks + 250 micrograms of levonorgestrel for the last 10 days
Trial: 1579323
Drug: 20-micrograms/24-hour levonorgestrel-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-micrograms/24-hour levonorgestrel-releasing intrauterine device (IUD) + 2 mg of estradiol valerate daily
Trial: 1579323
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Cyclic treatment and IUD)
Trial: 4044854
Drug: Non-treatment controls
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment controls (Institutionalized residents)
Trial: 4044854
Drug: Non-treatment controls
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-treatment controls (Staff counselors)
Trial: 31854463
Drug: Shoulder block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shoulder block (20 ml bupivacaine 0.5%)
Trial: 31854463
Drug: Interscalene block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene block (20 ml bupivacaine 0.5%)
Trial: 24355241
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of hyaluronic acid (HA) using Ialumar® nasal spray for 30 days
Trial: 24355241
Drug: Physiological solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological solution (control group) for 30 days
Trial: 21914589
Drug: Zonisamide (ZNS)
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide (ZNS) adjunctive therapy, dosage of 244.8 ± 108 mg/d at study end
Trial: 21914589
Drug: Zonisamide (ZNS)
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide (ZNS) adjunctive therapy
Trial: 14607015
Drug: Conventional paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional paracetamol tablets (1,500 mg) with morphine (10 mg 4 hourly for 12 hours prior)
Trial: 14607015
Drug: Conventional paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional paracetamol tablets (1,500 mg) without morphine
Trial: 14607015
Drug: Dispersible paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible paracetamol tablets (1,500 mg) with morphine (10 mg 4 hourly for 12 hours prior)
Trial: 14607015
Drug: Dispersible paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible paracetamol tablets (1,500 mg) without morphine
Trial: 11004039
Drug: 1% hypobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% hypobaric lidocaine 50 mg (Group L50)
Trial: 11004039
Drug: 1% hypobaric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% hypobaric lidocaine 20 mg + 25 microg fentanyl (Group L20/F25)
Trial: 31733786
Drug: Treadmill gait
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treadmill gait training together with traditional treatment
Trial: 27495291
Drug: Glimepiride (6-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (6-8 mg)
Trial: 27600862
Drug: Canagliflozin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (100 mg and 300 mg)
Trial: 20132586
Drug: Oil diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil diet (mean beta-carotene intake 3.1 mg/d)
Trial: 20132586
Drug: Mixed diet
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed diet (mean beta-carotene intake 7.6 mg/d)
Trial: 17714824
Drug: Repaglinide/Metformin/NPH (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide/Metformin/NPH (Group A)
Trial: 17714824
Drug: Metformin/NPH (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin/NPH (Group B)
Trial: 11967679
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg intravenous before extubation
Trial: 371319
Drug: Preoperative antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative antibiotic bowel preparation for 24 hours
Trial: 371319
Drug: Preoperative antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative antibiotic bowel preparation for 60 hours
Trial: 371319
Drug: Preoperative antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative antibiotic bowel preparation (both 24 and 60 hours)
Trial: 31609189
Drug: Long-acting injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting injection formulations of SGAs
Trial: 30400965
Drug: Opioid replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid replacement therapy
Trial: 24029470
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical treatment (control)
Trial: 14500162
Drug: Ropivacaine 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 3.75 mg/mL
Trial: 12191848
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 50 microg daily for 12 months
Trial: 12191848
Drug: Transdermal norethisterone
RxNorm normalized name: ethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal norethisterone acetate (NETA) continuously (170 or 350 microg/day)
Trial: 12191848
Drug: Sequential oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential oral NETA (1 mg/day)
Trial: 12191848
Drug: Dydrogesterone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone (20 mg/day)
Trial: 3428285
Drug: Carbimazole pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole pretreatment for a minimum of three months before 131I therapy
Trial: 3428285
Drug: 131I therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 131I therapy alone
Trial: 29121294
Drug: Buprenorphine i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine i.v. infusion (25 μg h ‐1 for 24 h)
Trial: 29121294
Drug: Morphine (equianalgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (equianalgesic dose)
Trial: 25637938
Drug: bupivacaine, 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine, 0.25% 30 mL
Trial: 25637938
Drug: bupivacaine, 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine, 0.25% 30 mL with 1‐mg dexamethasone
Trial: 25637938
Drug: bupivacaine, 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine, 0.25% 30 mL with 2‐mg dexamethasone
Trial: 25637938
Drug: bupivacaine, 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine, 0.25% 30 mL with 4‐mg dexamethasone
Trial: 25637938
Drug: dexamethasone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexamethasone (all doses)
Trial: 23948110
Drug: Drug eluting
RxNorm normalized name: Drug eluting stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug eluting stent (DES)
Trial: 16458131
Drug: Upstream use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upstream use of small molecule GP IIb/IIIa inhibitors for all ACS patients
Trial: 12758236
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus mitomycin C (MMC) (15 mg/m² single injection at the end of the first week of radiotherapy)
Trial: 10739392
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg aspirin/day p.o. for 11 days
Trial: 10739392
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin/day p.o. for 11 days
Trial: 10739392
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg L-aspirin infusion
Trial: 8157945
Drug: Pravastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10 mg for the first month, 20 mg for the second month, 40 mg for the remaining 4 months)
Trial: 3063660
Drug: Penfluridol, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penfluridol, administered once weekly
Trial: 3063660
Drug: Trifluoperazine, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluoperazine, administered twice daily
Trial: 28120856
Drug: l-arginine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine supplementation (2 g per day)
Trial: 24589310
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose MDCT
Trial: 24589310
Drug: Ultra-low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low dose MDCT
Trial: 20211294
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 81 to 324 mg once daily
Trial: 15298986
Drug: Unilateral Limb
RxNorm normalized name: BANDAGE TUBULAR ELAST TUBIFAST LG LIMB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral Limb Suspension (ULLS)
Trial: 9659857
Drug: 25 mg/day
RxNorm normalized name: estradiol 0.025 MG/Day Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/day of olanzapine
Trial: 9659857
Drug: 1200 mg/day
RxNorm normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg/day of chlorpromazine plus 4 mg/day of benztropine mesylate
Trial: 2500466
Drug: Extended treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended treatment of 40 weekly sessions
Trial: 2500466
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of 20 weekly sessions
Trial: 31226526
Drug: Citric acid/tetracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citric acid/tetracycline gel (CAT) group
Trial: 25684586
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 μg orally once daily
Trial: 21700430
Drug: Iloperidone 10-16
RxNorm normalized name: iloperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iloperidone 10-16 mg
Trial: 21700430
Drug: Iloperidone 20-24
RxNorm normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iloperidone 20-24 mg
Trial: 16701187
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL bupivacaine plus midazolam 2 mg
Trial: 16701187
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL bupivacaine plus midazolam 1 mg
Trial: 16701187
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL hyperbaric bupivacaine 0.5%
Trial: 11092646
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens 0.625 mg (combined with medroxyprogesterone acetate 2.5 mg daily in five women with uterus intact)
Trial: 9126089
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in the 20 mg group)
Trial: 1530172
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of lidocaine + 0.05 mg of fentanyl + 0.5 mg of pancuronium (group D)
Trial: 1530172
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of lidocaine + 0.05 mg of fentanyl (group B)
Trial: 1530172
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of lidocaine + 0.5 mg of pancuronium (group C)
Trial: 1530172
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of lidocaine (group A)
Trial: 1530172
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of lidocaine + 0.05 mg of fentanyl + 0.5 mg of pancuronium (group E) for safety evaluation
Trial: 27160164
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (twice a week for 12 months)
Trial: 22119927
Drug: Pentavac(®) vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavac(®) vaccine manufactured at large scale
Trial: 22119927
Drug: Pentavac(®) vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavac(®) vaccine manufactured at small scale
Trial: 20580361
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (IMN) 20 mg vaginally
Trial: 19205545
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus placebo
Trial: 10352617
Drug: NC100150 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NC100150 injection with respiratory gating
Trial: 9082765
Drug: Intranasal immunization
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal immunization with P6 (twice, with 2 weeks in between)
Trial: 9082765
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of rIL-2 and rIL-5
Trial: 1937985
Drug: gallopamil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallopamil (50 mg thrice daily)
Trial: 1937985
Drug: diltiazem (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diltiazem (60 mg thrice daily)
Trial: 6128086
Drug: Pirbuterol (PB)
DrugBank: Pirbuterol (DB01291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pirbuterol (PB) 20 mg three times daily
Trial: 6128086
Drug: Pirbuterol (PB)
DrugBank: Pirbuterol (DB01291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pirbuterol (PB) 20 mg and 30 mg doses
Trial: 28844499
Drug: Rindopepimut (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rindopepimut (500 μg admixed with 150 μg GM‐CSF) plus standard oral temozolomide (150–200 mg/m2 for 5 of 28 days) for 6–12 cycles or longer.
Trial: 28844499
Drug: Control (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (100 μg keyhole limpet haemocyanin) plus standard oral temozolomide (150–200 mg/m2 for 5 of 28 days) for 6–12 cycles or longer.
Trial: 19269731
Drug: No chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chlorhexidine treatment (Control)